Endonovo Therapeutics, Inc. (ENDV) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEndonovo Therapeutics, Inc. (ENDV) trades at $0.0001. Endonovo Therapeutics, Inc. is a biotechnology company focused on developing and distributing non-invasive Electroceutical medical devices for regenerative medicine. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ENDV: ENDV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENDV against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ENDV: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Endonovo Therapeutics, Inc. (ENDV) Healthcare & Pipeline Overview
Endonovo Therapeutics, Inc., operating in the biotechnology sector, develops and distributes non-invasive Electroceutical medical devices, including SofPulse, for regenerative medicine applications. The company targets palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain, positioning itself within the electroceuticals market.
What Is the Investment Thesis for ENDV?
Endonovo Therapeutics operates in the electroceuticals market, a growing segment within regenerative medicine. The company's focus on non-invasive devices offers a potential advantage over traditional treatments. The SofPulse device addresses a significant market for palliative treatment of soft tissue injuries and chronic wounds. However, the company's financial performance, as indicated by a negative P/E ratio of -0.04 and a market cap of $0.00B, raises concerns about its current profitability and valuation. The high beta of -9.79 suggests significant volatility. Future growth depends on successful clinical trials and regulatory approvals for its expanded applications, including cardiovascular and liver diseases. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty surrounding the company's long-term financial viability.
Based on FMP financials and quantitative analysis
ENDV Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.04 reflects the company's current lack of profitability.
- Beta of -9.79 suggests an inverse correlation with the market, but also indicates high volatility.
- The company's focus on electroceuticals positions it in a growing segment of the regenerative medicine market.
- SofPulse device targets a significant market for palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain.
Who Are ENDV's Competitors?
ENDV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.96 | -0.06% | $624M | 885-pillar |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ENDV's Key Strengths?
Proprietary Electroceutical technology
- Non-invasive treatment approach
- Potential for expanded applications
- Focus on regenerative medicine
What Are ENDV's Weaknesses?
Limited financial resources
- Lack of profitability
- Dependence on regulatory approvals
- OTC market trading
What Could Drive ENDV Stock Higher?
Clinical trial results for SofPulse in treating chronic wounds.
- Regulatory approvals for expanded applications of Electroceuticals in cardiovascular disease.
- Research and development of new Electroceutical devices for regenerative medicine.
- Partnerships with healthcare providers for product adoption and distribution.
- Expansion into international markets.
What Are the Key Risks for ENDV?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for new applications.
- Competition from established pharmaceutical companies and medical device manufacturers.
- Negative clinical trial results for SofPulse or other Electroceutical devices.
- Limited financial resources and lack of profitability.
- Risks associated with OTC market trading, including low liquidity and potential for price manipulation.
What Are the Growth Opportunities for ENDV?
- Expansion of SofPulse Applications: Endonovo Therapeutics has the opportunity to expand the applications of its SofPulse device beyond its current indications. Timeline: Ongoing clinical trials with potential results within the next 12-24 months.
- Treatment of Cardio Chronic Kidney Disease: The company is exploring the use of its Electroceuticals medical device for the treatment of cardio chronic kidney disease. This represents a significant market opportunity, as chronic kidney disease affects millions of people worldwide. Successful development and commercialization of this application could drive substantial revenue growth. Timeline: Pre-clinical and early clinical trials ongoing, with potential for Phase 2 trials within 2-3 years.
- Treatment of Liver Disease NASH: Endonovo Therapeutics is also targeting liver disease non-alcoholic steatohepatitis (NASH) with its Electroceuticals technology. NASH is a growing health concern with limited treatment options, presenting a substantial market opportunity. Timeline: Pre-clinical studies underway, with potential for clinical trials in 3-5 years.
- Cardiovascular and Peripheral Artery Disease (PAD) Applications: The company is investigating the use of its Electroceuticals device for cardiovascular and peripheral artery disease (PAD). These conditions affect a large segment of the population, and a non-invasive treatment option could be highly valuable. Timeline: Early-stage research and development, with potential for pre-clinical studies in 2-3 years.
- Ischemic Stroke Treatment: Endonovo Therapeutics is exploring the application of its Electroceuticals technology for the treatment of ischemic stroke. Stroke is a leading cause of disability and death, and new treatment options are urgently needed. Timeline: Early-stage research and development, with potential for pre-clinical studies in 3-5 years.
What Opportunities Does ENDV Have?
- Expansion into new therapeutic areas
- Partnerships with healthcare providers
- International market expansion
- Growing demand for non-invasive therapies
What Are ENDV's Competitive Advantages?
- Proprietary Electroceutical technology
- Patents protecting device designs and applications
- First-mover advantage in specific electroceutical applications
- Potential for strong brand recognition with successful clinical outcomes
What Does ENDV Do?
Endonovo Therapeutics, Inc., founded in 2008 and headquartered in Woodland Hills, California, is a biotechnology company specializing in the development, manufacture, and distribution of non-invasive Electroceutical medical devices. The company's core focus is regenerative medicine, with a mission to provide innovative solutions for various medical conditions through its proprietary technology. Its flagship product, SofPulse, is a non-invasive Electroceutical therapeutic device designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond SofPulse, Endonovo Therapeutics is exploring the application of its Electroceuticals medical device for treating a range of conditions, including cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, peripheral artery disease (PAD), and ischemic stroke. The company's business model centers on the development, manufacturing, and marketing of these devices to healthcare providers and patients. Endonovo Therapeutics operates primarily in the United States, with potential for future expansion into international markets as regulatory approvals are secured for its various applications.
What Products and Services Does ENDV Offer?
- Develops non-invasive Electroceutical medical devices.
- Manufactures Electroceutical devices for regenerative medicine.
- Distributes Electroceutical devices to healthcare providers and patients.
- Offers SofPulse, a therapeutic device for soft tissue injuries, chronic wounds, and post-operative pain.
- Researches and develops new applications for Electroceutical technology.
- Targets treatment of cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke.
How Does ENDV Make Money?
- Develops and patents Electroceutical medical device technology.
- Manufactures and distributes SofPulse for palliative treatment.
- Seeks regulatory approvals for expanded applications of Electroceuticals.
- Partners with healthcare providers for product adoption and distribution.
What Industry Does ENDV Operate In?
Endonovo Therapeutics operates within the biotechnology industry, specifically focusing on the electroceuticals market. This market is experiencing growth driven by increasing demand for non-invasive therapies and advancements in medical device technology. The competitive landscape includes companies developing similar electroceutical devices and traditional pharmaceutical companies offering alternative treatments. Endonovo's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong market presence. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Who Are ENDV's Key Customers?
- Hospitals and clinics
- Physicians and medical professionals
- Patients with soft tissue injuries, chronic wounds, and post-operative pain
- Patients with cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke (future)
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 43 |
| 2026-08-26 | 43 |
| 2026-08-29 | 43 |
| 2026-09-01 | 43 |
| 2026-09-04 | 43 |
| 2026-09-07 | 43 |
| 2026-09-10 | 43 |
What changed?
The score has stayed at 43.
Over the same 18 days the stock moved +0.0%.
Key Financial Metrics
Return on equity for Endonovo Therapeutics, Inc. stands at 7.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
ENDV Revenue & Earnings Trend
In Q2 FY2026, ENDV generated $0 in top-line revenue. The company recorded a net loss of $588K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ENDV averaged $-0.00 in diluted EPS.
Company Profile
Endonovo Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woodland Hills, US. The company is led by CEO Alan Brian Collier. ENDV has traded publicly since 2012.
Financial Health
Endonovo Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
The most recent 12 insider filings for Endonovo Therapeutics, Inc. break down as 0 sales and 12 purchases. On net that is roughly 2K shares acquired (about $1K) — insiders putting money in tends to read as conviction.
ENDV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary Electroceutical technology
- Non-invasive treatment approach
- Potential for expanded applications
- Focus on regenerative medicine
Bear Case
- Limited financial resources
- Lack of profitability
- Dependence on regulatory approvals
- OTC market trading
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$588,365 | -$0.0003 |
| Q1 FY2026 | $0 | -$586,475 | -$0.0003 |
| Q4 FY2025 | $0 | -$540,972 | -$0.0003 |
| Q3 FY2025 | $0 | -$544,284 | -$0.0003 |
Q2 FY2026 · filed 30 Jun 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
ENDV Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 17, 2019
ENDV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ENDV.
Price Targets
Wall Street price target analysis for ENDV.
ENDV MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ENDV; grades run from A+ (80-100) to F (below 30).
ENDV OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Endonovo Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading in these securities carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies that are distressed, defunct, or unwilling to provide current information.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or scams
- Lack of regulatory oversight
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company has been in operation since 2008.
- Focus on developing medical devices for regenerative medicine.
- SofPulse device targets a specific market for palliative treatment.
- Company has a website and publishes press releases.
Endonovo Therapeutics, Inc. Healthcare Stock: Key Questions Answered
Is ENDV a good stock?
Stock Expert AI does not rate ENDV buy, sell or hold. Endonovo Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about ENDV stock?
Given the company's OTC listing, limited financial information, and lack of profitability, analysts may express caution regarding its investment potential. Key valuation metrics, such as the negative P/E ratio, reflect the company's current financial challenges.
What are the key factors to evaluate for ENDV?
Evaluate ENDV on fundamentals, analyst consensus, and risk factors. The SofPulse device addresses a significant market for palliative treatment of soft tissue injuries and chronic wounds. Not financial advice.
How frequently does ENDV data refresh on this page?
ENDV's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ENDV's recent stock price performance?
Endonovo Therapeutics, Inc. (ENDV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Electroceutical technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENDV overvalued or undervalued right now?
Endonovo Therapeutics, Inc. (ENDV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ENDV?
Yes, most major brokerages offer fractional shares of Endonovo Therapeutics, Inc. (ENDV) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ENDV's earnings and financial reports?
Endonovo Therapeutics, Inc. (ENDV) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ENDV earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-traded companies.
- Financial data may not be current or audited.